Ryvu Therapeutics (LTS:0RKT) Cyclically Adjusted FCF per Share: zł-5.23 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKT Ryvu Therapeutics SA LTS:0RKT
66 GF Score
Price zł30.25
GF Value zł93.11
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Cyclically Adjusted FCF per Share?

Ryvu Therapeutics LTS:0RKT 66 Cyclically Adjusted FCF per Share is zł-5.23 as of Mar. 2026. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł93.11. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ryvu Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was zł-1.018. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is zł-5.23 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -17.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Ryvu Therapeutics was -14.20% per year. The lowest was -17.10% per year. And the median was -15.65% per year.

As of today (2026-07-21), Ryvu Therapeutics's current stock price is zł30.25. Ryvu Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was zł-5.23. Ryvu Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Ryvu Therapeutics  (LTS:0RKT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ryvu Therapeutics Cyclically Adjusted FCF per Share Related Terms


Ryvu Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics Cyclically Adjusted FCF per Share Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -3.17 -4.12

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.65 -3.41 -3.98 -4.12 -5.23

LTS:0RKT vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Ryvu Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


LTS:0RKT
66GF Score
Ryvu Therapeutics SA LTS:0RKT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ryvu Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.018/163.0700*163.0700
=-1.018

Current CPI (Mar. 2026) = 163.0700.

Ryvu Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.557 99.552 -0.912
201609 -0.196 99.064 -0.323
201612 -1.207 100.366 -1.961
201703 -1.720 101.018 -2.777
201706 2.037 101.180 3.283
201709 -0.436 101.343 -0.702
201712 -0.619 102.564 -0.984
201803 -0.554 102.564 -0.881
201806 0.351 103.378 0.554
201809 -0.586 103.378 -0.924
201812 -1.971 103.785 -3.097
201903 -2.067 104.274 -3.233
201906 1.247 105.983 1.919
201909 -0.660 105.983 -1.016
201912 -1.113 107.123 -1.694
202003 -1.284 109.076 -1.920
202006 -0.583 109.402 -0.869
202009 -0.559 109.320 -0.834
202012 -0.306 109.565 -0.455
202103 -0.725 112.658 -1.049
202106 -1.773 113.960 -2.537
202109 -1.212 115.588 -1.710
202112 -0.152 119.088 -0.208
202203 -1.238 125.031 -1.615
202206 -1.091 131.705 -1.351
202209 -0.282 135.531 -0.339
202212 3.293 139.113 3.860
202303 -1.523 145.950 -1.702
202306 -1.092 147.009 -1.211
202309 -0.409 146.113 -0.456
202312 -1.038 147.741 -1.146
202403 -1.904 149.044 -2.083
202406 -1.112 150.997 -1.201
202409 -1.635 153.439 -1.738
202412 -1.198 154.660 -1.263
202503 -1.943 157.021 -2.018
202506 -1.107 157.509 -1.146
202509 -0.842 158.000 -0.869
202512 -1.424 158.320 -1.467
202603 -1.018 163.070 -1.018

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of zł-5.23 mean?
Ryvu Therapeutics (LTS:0RKT) has a Cyclically Adjusted FCF per Share of zł-5.23 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' Cyclically Adjusted FCF per Share too high?
Ryvu Therapeutics' current Cyclically Adjusted FCF per Share is zł-5.23. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Ryvu Therapeutics' Cyclically Adjusted FCF per Share of zł-5.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current Cyclically Adjusted FCF per Share is zł-5.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Cyclically Adjusted FCF per Share of zł-5.23. The stock's GF Value™ is zł93.11, compared to a current price of zł30.25 — trading 67.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is zł-5.23. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Cyclically Adjusted FCF per Share is zł-5.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł30.25 is trading 67.5% below its estimated GF Value™ of zł93.11.

Key valuation signals for LTS:0RKT:

  • Cyclically Adjusted FCF per Share: zł-5.23
  • GF Value™: zł93.11 vs. price of zł30.25 (67.5% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for LTS:0RKT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.25
Price
zł93.11
GF Value